Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Page 1
Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
Liu J, Zhou Y, Zhang L, Li Z, Chen W, Zhu Y, Yao X, Zhang L, Liu S, Peng Y, Wei M, Zhang Q, Shu H, Wang S, Liu W, Wan S, Li T, Fang Y, Han H, Zhang G, Huang L, Wang F, Cheng G, Gao L, Shi H, Han J, Luo Y, Li S, Cai C, Yin R, Jin Z, Shao C, Tian B, Zhang Y, Li Q, Zhang Y, Zhang P, Li B, Xing P, Shen H, Zhu X, Zhang X, Hua W, Shen F, Huyan M, Chen R, Zuo Q, Li Q, Huang Q, Xu Y, Deng B, Zhao R, Goyal M, Zhang Y, Yang P; PROTECT-MT Investigators. Liu J, et al. Lancet. 2024 Nov 20:S0140-6736(24)02315-8. doi: 10.1016/S0140-6736(24)02315-8. Online ahead of print. Lancet. 2024. PMID: 39579782
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. Bossi A, et al. Lancet. 2024 Nov 23;404(10467):2065-2076. doi: 10.1016/S0140-6736(24)01865-8. Lancet. 2024. PMID: 39580202 Clinical Trial.
Pembrolizumab for locally advanced cervical cancer.
Dong B, Lu Y, Wang Y, Sun P, Zou H. Dong B, et al. Lancet. 2024 Nov 23;404(10467):2050. doi: 10.1016/S0140-6736(24)02230-X. Lancet. 2024. PMID: 39580200 No abstract available.
Pembrolizumab for locally advanced cervical cancer.
Schmid MP, Petric P, Mahantshetty U, Kirisits C, Tanderup K, Jürgenliemk-Schulz I, Lindegaard J, Pötter R. Schmid MP, et al. Lancet. 2024 Nov 23;404(10467):2050-2051. doi: 10.1016/S0140-6736(24)02231-1. Lancet. 2024. PMID: 39580199 No abstract available.
Pembrolizumab for locally advanced cervical cancer.
Murakami N, Okonogi N, Terao Y, Shikama N. Murakami N, et al. Lancet. 2024 Nov 23;404(10467):2049-2050. doi: 10.1016/S0140-6736(24)02229-3. Lancet. 2024. PMID: 39580197 No abstract available.
UNRWA's work is at risk again.
Hamad BA, Jamaluddine Z, Aly S, Salayma M, Asi Y, Mowafi H, Checchi F, Sato M, Bali A, Spiegel P. Hamad BA, et al. Lancet. 2024 Nov 20:S0140-6736(24)02476-0. doi: 10.1016/S0140-6736(24)02476-0. Online ahead of print. Lancet. 2024. PMID: 39579781 No abstract available.
19 results